Ultragenyx Pharmaceutical (RARE) Interest Expenses (2013 - 2026)
Ultragenyx Pharmaceutical (RARE) posted quarterly Interest Expenses of $21.0 million for Q1 2026, up 50.0% year-over-year from $14.0 million in Q1 2025, and up 7.86% quarter-over-quarter from $19.5 million in Q4 2025.
Ultragenyx Pharmaceutical (RARE) Interest Expenses (2013 - 2026) Analysis & Trends
Ultragenyx Pharmaceutical (RARE) has reported Interest Expenses for 14 consecutive years, with $21.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest Expenses rose 50.0% year-over-year to $21.0 million; the TTM figure through Mar 2026 stood at $68.7 million (up 12.27% YoY), while the FY2025 annual figure was $62.0 million, down 1.59% from the prior year.
- Interest Expenses improved to $21.0 million in Q1 2026 per RARE's latest filing, from $19.5 million in the prior quarter.
- Across five years, Interest Expenses topped out at $21.0 million in Q1 2026 and bottomed at $6.6 million in Q1 2022.
- Historically, Interest Expenses has averaged $15.1 million across 5 years, with a median of $15.6 million in 2023.
- On a YoY basis, Interest Expenses climbed as much as 317.3% in 2022 and fell as far as 21.79% in 2022.
- Ultragenyx Pharmaceutical's Interest Expenses stood at $15.9 million in 2022, then gained by 9.13% to $17.3 million in 2023, then decreased by 10.64% to $15.5 million in 2024, then climbed by 25.76% to $19.5 million in 2025, then increased by 7.86% to $21.0 million in 2026.
- Business Quant data shows RARE's Interest Expenses at $21.0 million in Q1 2026, $19.5 million in Q4 2025, and $14.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Ultragenyx Pharmaceutical | 2.61 Bn | 2.33 Bn | 180.00 Mn | 22.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 22.00 Mn |
| Jun 30, 2026 | 22.00 Mn |
| Mar 31, 2026 | 21.00 Mn |
| Mar 31, 2026 | 21.00 Mn |
| Dec 31, 2025 | 19.47 Mn |
| Dec 31, 2025 | 19.47 Mn |
| Sep 30, 2025 | 14.15 Mn |
| Sep 30, 2025 | 14.15 Mn |
| Jun 30, 2025 | 14.04 Mn |
| Jun 30, 2025 | 14.04 Mn |
| Mar 31, 2025 | 14.00 Mn |
| Mar 31, 2025 | 14.00 Mn |
| Dec 31, 2024 | 15.48 Mn |
| Dec 31, 2024 | 15.48 Mn |
| Sep 30, 2024 | 15.71 Mn |
| Sep 30, 2024 | 15.71 Mn |
| Jun 30, 2024 | 15.96 Mn |
| Jun 30, 2024 | 15.96 Mn |
| Mar 31, 2024 | 15.85 Mn |
| Mar 31, 2024 | 15.85 Mn |